Collectively, these findings indicate that CD56 by itself is an inadequate marker of functional CD56bright NK cells in bladder tumors and is associated with nonluminal bladder tumor subtype and poor survival outcomes. This evidence concerns the gene NCAM1 and urinary bladder neoplasm.